VKTXViking Therapeutics, Inc.
Price
+12%1YEnd-of-day closes, not the intraday tick.
RyuScore
Weak, higher than 5% of companiesThe five questions
2 of 5 availableOnly two of the five can be answered for VKTX today. The rest need figures this filer has not published. The tabs above still show whatever data does exist.
- Is the business good?not enough filed
- Is it safe?Mixed
- Is the price fair?not enough filed
- Is it growing?not enough filed
- What is the market doing?Watch
We are a clinical-stage biopharmaceutical company focused on the development of novel, first-in-class or best-in-class therapies for metabolic and endocrine disorders. In January 2022, we announced the initiation of a Phase 1 single ascending dose, or SAD, and multiple ascending dose, or MAD, clinical trial of VK2735, a novel dual agonist of the glucagon-like peptide 1, or GLP-1, and glucose-dependent insulinotropic polypeptide, or GIP, receptors.
In the company’s own words · 10-K filed Feb 11, 2026 · SEC EDGAR
Charts
As reported to the SEC, without any scoring.
Viking Therapeutics, Inc. (VKTX) reported revenue of $0 in Q2 2026 (quarter ended Jun 30, 2026). That came with net loss of $128M. For the full year FY2025, revenue was $0 and net income −$360M. The next results filing is expected around Oct 21, 2026, the same week as a year ago.
What the company said
The company's own words from its current reports to the SEC, newest first
- Sep 28, 2026Equity Offering On September 23, 2026, Viking Therapeutics, Inc. (the “Company”) entered into an underwriting agreement (the “Equity Underwriting Agreement”) with Morgan Stanley & Co. LLC and J.P. Morgan Securities LLC (the “Equity Representatives”), as representatives of the several underwriters named therein (the …Material agreement entered · Form 8-K
- Sep 22, 2026On September 22, 2026, Viking Therapeutics, Inc. issued a press release announcing top-line results from its maintenance study of GLP-1/GIP agonist VK2735.Other event · Form 8-K
- Jul 29, 2026Viking Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update.Earnings release · press release
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.